Gastroesophageal Cancer – Landscape & Forecast – Disease Landscape & Forecast

The gastroesophageal cancer market (including gastric, gastroesophageal junction, and esophageal cancer) is witnessing a substantial change, largely fueled by the entry of immune checkpoint inhibitor combination therapies. We expect that label expansions of Opdivo (Bristol Myers Squibb) and Keytruda (Merck & Co.), as well as approvals of other programmed death-ligand 1 (PD-L1) and programmed cell death-1 (PD-1) inhibitors, will continue to reshape the human epidermal growth factor receptor-2 (HER2)-negative gastroesophageal cancer market in the coming years. Immune checkpoint inhibitors in combination with HER2-targeted agents and chemotherapy, and the anti-HER2 antibody-drug conjugate Enhertu (Daiichi Sankyo / AstraZeneca) are poised to expand treatment options for HER2-positive patients. Other treatments are targeting niche biomarkers (e.g., claudin18.2, FGFR2b) and are set to provide novel treatment options for select gastroesophageal cancer patients. Given the intense late-phase pipeline activity, we anticipate the approval of several new therapies for gastroesophageal cancer during the forecast period.

Questions answered

  • How is gastroesophageal cancer segmented by subpopulation, and how will the recent drug approvals and label expansions to the various subpopulations impact the market?
  • What are the key current therapies in gastroesophageal cancer, and how are they positioned in the treatment algorithm?
  • Which emerging therapies are the most promising, and how will they shape the future of the gastroesophageal cancer market?
  • What are the drivers and constraints in the gastroesophageal cancer market, and how will the market evolve over the forecast period?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement

Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

  • Gastroesophageal Cancer - Landscape & Forecast - Disease Landscape & Forecast
    • Key findings
      • Key updates
        • January 2023
        • Q4 2022
          • December 2022
        • Q3 2022
          • July 2022
        • Q2 2022
          • April 2022
        • Q1 2022
          • March 2022
          • February 2022
          • January 2022
        • Q4 2021
          • December 2021
      • Market outlook
        • Key findings
          • Major-market share of drug classes in gastroesophageal cancer: 2021
          • Major-market share of drug classes in gastroesophageal cancer: 2031
          • Major-market sales of key therapies for gastroesophageal cancer: 2021-2031
          • Drug-treatable population share and major-market sales share in gastroesophageal cancer: 2021
          • Drug-treatable population share and major-market sales share in gastroesophageal cancer: 2031
          • Population positioning of therapies in gastric and GEJ cancer: United States and Europe
          • Population positioning of therapies in gastric and GEJ cancer: Japan
          • Population positioning of therapies in esophageal cancer: United States and Europe
          • Population positioning of therapies in esophageal cancer: Japan
          • Gastroesophageal cancer SWOT analysis
        • Market drivers and constraints
          • What factors are driving the market for gastroesophageal cancer?
          • What factors are constraining the market for gastroesophageal cancer?
        • Segment-specific trends
          • Patient-share dynamics of key regimens in resectable gastric and gastroesophageal junction adenocarcinoma in the United States: 2021-2031
          • Patient-share dynamics of key regimens in resectable esophageal cancer in the United States: 2021-2031
          • Patient-share dynamics of key regimens in unresectable locally advanced HER2-negative gastric and GEJ adenocarcinoma in the United States: 2021-2031
          • Patient-share dynamics of key regimens in unresectable locally advanced HER2-positive gastric and GEJ adenocarcinoma in the United States: 2021-2031
          • Patient-share dynamics of key regimens in unresectable locally advanced esophageal cancer in the United States: 2021-2031
          • Patient-share dynamics of key regimens in first-line metastatic HER2-negative gastric and gastroesophageal junction adenocarcinoma in the United States: 2021-2031
          • Patient-share dynamics of key regimens in first-line metastatic HER2-positive gastric and gastroesophageal junction adenocarcinoma in the United States: 2021-2031
          • First-line metastatic esophageal adenocarcinoma and squamous cell carcinoma
          • Patient-share dynamics of key regimens in first-line metastatic esophageal adenocarcinoma in the United States: 2021-2031
          • Patient-share dynamics of key regimens in first-line metastatic esophageal squamous cell carcinoma in the United States: 2021-2031
          • Patient-share dynamics of key regimens in second-line metastatic HER2-negative gastric and gastroesophageal junction adenocarcinoma in the United States: 2021-2031
          • Patient-share dynamics of key regimens in second-line metastatic HER2-positive gastric and gastroesophageal junction adenocarcinoma in the United States: 2021-2031
          • Patient-share dynamics of key regimens in second- and third-line metastatic esophageal adenocarcinoma in the United States: 2021-2031
          • Patient-share dynamics of key regimens in second- and third-line metastatic esophageal squamous cell carcinoma in the United States: 2021-2031
          • Patient-share dynamics of key regimens in third- and fourth-line metastatic HER2-negative gastric and gastroesophageal junction adenocarcinoma in the United States: 2021-2031
          • Patient-share dynamics of key regimens in third- and fourth-line metastatic HER2-positive gastric and gastroesophageal junction adenocarcinoma in the United States: 2020-2030
      • Forecast
        • Market forecast assumptions
        • Market forecast dashboard
      • Etiology and pathophysiology
        • Disease overview
          • Disease pathophysiology
            • Anatomy of the stomach and the gastroesophageal junction
            • Anatomy of the esophagus
            • Subtype classification and development of gastric and gastroesophageal junction adenocarcinoma
            • Key stages in the development of intestinal and diffuse types of gastric andu00a0gastroesophageal junctionu00a0adenocarcinoma
            • Subtype classification and development of esophageal cancer
            • Key stages in the development of esophageal cancer
          • Staging and classification
            • AJCC / UICC TNM classification system for gastroesophageal cancer
            • AJCC / UICC clinical staging classification system for gastroesophageal cancer
            • AJCC / UICC pathological staging classification system for gastroesophageal cancer
            • AJCC / UICC postneoadjuvant therapy staging classification system for gastroesophageal cancer
          • Key pathways and drug targets
            • Drug targets and potential therapies for gastroesophageal cancer
            • Drug targets for gastroesophageal cancer
            • Biology of immune checkpoint inhibitors and modulators
        • Epidemiology
          • Introduction
            • Key findings
          • Epidemiology populations
            • Disease definition
            • Methods and sources used
            • Number of diagnosed incident cases of gastroesophageal cancer: 2021-2031
            • Definition
            • Methods and sources used
            • Diagnosed incident cases of gastric and GEJ adenocarcinoma by stage distribution: 2021-2031
            • Diagnosed incident cases of esophageal adenocarcinoma by stage distribution: 2021-2031
            • Diagnosed incident cases of esophageal squamous cell carcinoma by stage distribution: 2021-2031
            • Definition
            • Methods and sources used
            • Recurrent incident cases of gastroesophageal cancer: 2021-2031
            • Definition
            • Methods and sources used
            • Molecular subtype: 2021-2031
            • Gastric and gastroesophageal junction adenocarcinoma patient flow
            • Esophageal adenocarcinoma patient flow
            • Esophageal squamous cell carcinoma patient flow
            • Drug-treatable cases of gastroesophageal cancer: 2021-2031
            • Drug-treated populations
            • Drug-treated cases of gastroesophageal cancer: 2021-2031
        • Current treatment
          • Key findings
            • Treatment goals
              • Key endpoints used in clinical trials for gastroesophageal cancer
            • Key current therapies
              • Overview
              • Mechanism of action of key current drug classes used for gastroesophageal cancer
              • Current treatments used for gastroesophageal cancer
              • Market events impacting the use of key current therapies for gastroesophageal cancer
              • Key results from select clinical trials investigating Cyramza for the treatment of gastroesophageal cancer
              • Ongoing clinical development of Cyramza
              • Key ongoing clinical trials of Cyramza in the treatment of gastroesophageal cancer
              • Expert insight: Cyramza
              • Key results from select clinical trials investigating trastuzumab for the treatment of gastroesophageal cancer
              • Ongoing clinical development of trastuzumab
              • Expert insight: trastuzumab
              • Key results from select clinical trials investigating Enhertu for the treatment of gastroesophageal cancer
              • Ongoing clinical development of Enhertu
              • Key ongoing clinical trials of Enhertu in the treatment of gastroesophageal cancer
              • Expert insight: Enhertu
              • Key results from select clinical trials investigating Keytruda for the treatment of gastroesophageal cancer
              • Ongoing clinical development of Keytruda
              • Key ongoing clinical trials of Keytruda in the treatment of gastroesophageal cancer
              • Expert insight: Keytruda
              • Key results from select clinical trials investigating Opdivo for the treatment of gastroesophageal cancer
              • Ongoing clinical development of Opdivo
              • Key ongoing clinical trials of Opdivo in the treatment of gastroesophageal cancer
              • Expert insight: Opdivo
              • Lonsurf
              • Key results from select clinical trials investigating Lonsurf for the treatment of gastroesophageal Cancer
              • Ongoing clinical development of Lonsurf
              • Expert insights: Lonsurf
            • Medical practice
              • Localized and resectable locally advanced gastroesophageal cancer
              • Unresectable locally advanced gastroesophageal cancer
              • First-line metastatic gastroesophageal cancer
              • Second-line gastroesophageal cancer
              • Patient characteristics influencing drug selection in gastroesophageal cancer
              • Region-specific treatment practices
              • Treatment decision tree for drug-treatable gastric and gastroesophageal junction adenocarcinoma: United States
              • Treatment decision tree for drug-treatable esophageal cancer: United States
              • Treatment decision tree for drug-treatable gastric and gastroesophageal junction adenocarcinoma: Europe
              • Treatment decision tree for drug-treatable esophageal cancer: Europe
              • Treatment Decision Tree for drug-treatable Gastric and Gastroesophageal Junction Adenocarcinoma: Japan
              • Treatment Decision Tree for drug-treatable Esophageal Cancer: Japan
          • Unmet need overview
            • Current and future attainment of unmet needs in gastroesophageal cancer
            • Top unmet needs in gastroesophageal cancer: current and future attainment
            • Expert insights: unmet need in gastroesophageal cancer
          • Drug pipeline
            • Pipeline
            • Regulatory Milestones
            • Indication Comparison
          • Emerging therapies
            • Key findings
              • Key emerging therapies
                • Key therapies in development for gastroesophageal cancer
                • Estimated market authorization dates of key emerging therapies for the treatment of gastroesophageal cancer
                • Key results from select clinical trials investigating tislelizumab for the treatment of gastroesophageal cancer
                • Key ongoing clinical trials of tislelizumab in the treatment of gastroesophageal cancer
                • Analysis of clinical development program for tislelizumab
                • Expert insight: tislelizumab
                • Expectations for market authorization and sales opportunity of tislelizumab in gastroesophageal cancer
                • Key results from select clinical trials investigating Imfinzi for the treatment of gastroesophageal cancer
                • Key ongoing clinical trials of Imfinzi in the treatment of gastroesophageal cancer
                • Analysis of clinical development program for Imfinzi
                • Expert insight: Imfinzi
                • Expectations for market authorization and sales opportunity of Imfinzi in gastroesophageal cancer
                • Key results from select clinical trials investigating Tecentriq / Tecentriq plus tiragolumab for the treatment of gastroesophageal cancer
                • Key ongoing clinical trials of Tecentriq / Tecentriq plus tiragolumab in the treatment of gastroesophageal cancer
                • Analysis of clinical development program for Tecentriq / Tecentriq plus tiragolumab
                • Expert insights: Tecentriq / Tecentriq plus tiragolumab
                • Expectations for market authorization and sales opportunity of Tecentriq / Tecentriq plus tiragolumab in gastroesophageal cancer
                • Key results from select clinical trials investigating Tyvyt for the treatment of gastroesophageal cancer
                • Key ongoing clinical trials of Tyvyt in the treatment of gastroesophageal cancer
                • Analysis of clinical development program for Tyvyt
                • Expert insights: Tyvyt
                • Expectations for market authorization and sales opportunity of Tyvyt in gastroesophageal cancer
                • Key results from select clinical trials investigating evorpacept for the treatment of gastroesophageal cancer
                • Key ongoing clinical trials of evorpacept in the treatment of gastroesophageal cancer
                • Analysis of clinical development program for evorpacept
                • Expectations for market authorization and sales opportunity of evorpacept in gastroesophageal cancer
                • Key results from select clinical trials investigating zanidatamab for the treatment of gastroesophageal cancer
                • Key ongoing clinical trials of zanidatamab in the treatment of gastroesophageal cancer
                • Analysis of clinical development program for zanidatamab
                • Expert insight: zanidatamab
                • Expectations for market authorization and sales opportunity of zanidatamab in gastroesophageal cancer
                • Key results from select clinical trials investigating Margenza for the treatment of gastroesophageal cancer
                • Key ongoing clinical trials of Margenza in the treatment of gastroesophageal cancer
                • Analysis of clinical development program for Margenza
                • Expectations for market authorization and sales opportunity of Margenza in gastroesophageal cancer
                • Tukysa
                • Key ongoing clinical trials of Tukysa in the treatment of gastroesophageal cancer
                • Analysis of clinical development program for Tukysa
                • Expert insight: Tukysa
                • Expectations for market authorization and sales opportunity of Tukysa in gastroesophageal cancer
                • Key results from select clinical trials investigating rivoceranib for the treatment of gastroesophageal cancer
                • Analysis of clinical development program for rivoceranib
                • Expert insight: rivoceranib
                • Expectations for market authorization and sales opportunity of rivoceranib in gastroesophageal cancer
                • Key results from select clinical trials investigating Stivarga for the treatment of gastroesophageal cancer
                • Key ongoing clinical trials of Stivarga in the treatment of gastroesophageal cancer
                • Analysis of clinical development program for Stivarga
                • Expert insight: Stivarga
                • Expectations for market authorization and sales opportunity of Stivarga in gastroesophageal cancer
                • Key results from select clinical trials investigating Lenvima for the treatment of gastroesophageal cancer
                • Key ongoing clinical trials of Lenvima in the treatment of gastroesophageal cancer
                • Analysis of the clinical development program for Lenvima
                • Expert insight: Lenvima
                • Expectations for market authorization and sales opportunity of Lenvima in gastroesophageal cancer
                • Key results from select clinical trials investigating zolbetuximab for the treatment of gastroesophageal cancer
                • Key ongoing clinical trials of zolbetuximab in the treatment of gastroesophageal cancer
                • Analysis of clinical development program for zolbetuximab
                • Expert insight: zolbetuximab
                • Bemarituzumab
                • Key results from select clinical trials investigating bemarituzumabu00a0for the treatment of gastroesophageal cancer
                • Key ongoing clinical trials of bemarituzumab in the treatment of gastroesophageal cancer
                • Analysis of clinical development program for bemarituzumabu00a0
                • Expert insight: bemarituzumab
                • Expectations for market authorization and sales opportunity of bemarituzumab in gastroesophageal cancer
              • Early-phase pipeline analysis
                • Select compounds in early-phase development for gastroesophageal cancer
            • Access and reimbursement overview
              • Region-specific reimbursement practices
                • Key market access considerations in gastroesophageal cancer: United States
                • General reimbursement environment: United States
                • Key market access considerations in gastroesophageal cancer: EU5
                • General reimbursement environment: EU5
                • Key market access considerations in gastroesophageal cancer: Japan
                • General reimbursement environment: Japan
            • Appendix
              • Abbreviations
              • Gastroesophageal cancer bibliography

          Login to access report